Navigation Links
Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients
Date:3/24/2009

ensive care units and other hospital settings.

"Since 2003, AACE and the ADA have worked together to provide recommendations for treatment of inpatient hyperglycemia, and these efforts have contributed to a growing national movement viewing the management of hyperglycemia in hospitals as a quality care measure," Dr. Etie S. Moghissi, AACE Chair of Inpatient Glycemic Control Task Force said.

Recognizing the critical importance of controlling hyperglycemic states in conjunction with the results of recent randomized trials such as NICE-SUGAR, the two organizations recently convened a Consensus Panel to extensively review the most current literature and up-to-date recommendations for treatment of hyperglycemia in the hospital.

"The central goal of the ADA/AACE inpatient task force is to identify reasonable, achievable, and safe glucose targets, and to describe the protocols, procedures, and system improvements needed to achieve inpatient optimal glucose control efficiently and safely," Dr. Mary Korytkowski, ADA Chair of Inpatient Glycemic Control Task Force said.

Complete recommendations from the panel will be published in Endocrine Practice and Diabetes Care later in the spring. Until more information is available, it seems reasonable for clinicians to treat critical care patients with the less intensive - yet good - glucose control strategies used in the conventional arm of the NICE-SUGAR trial.

About The NICE-SUGAR Study

Hyperglycemia in the hospital, whether it occurs in patients with known diabetes or is temporarily stress-induced, has long been known to be associated with poor outcomes such as longer length of stay, increased rates of infection, and in-hospital death. Observational studies and early randomized trials have suggested that lowering glucose levels can improve outcomes, especially in critical care patients treated with
'/>"/>

SOURCE American Association of Clinical Endocrinologists; American Diabetes Association
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. A Joint Statement From Americas Prostate Cancer Advocacy, Education, and Support Organizations
2. Octogenarians: Not Too Old for Joint Replacement
3. Beating Blood Clots after Joint Replacement
4. When to Have That Joint Replacement?
5. Orthopaedic Surgeon Shortage Predicted Due to Soaring Joint Replacement Procedures
6. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
7. Texas Back Institute Leads Way in New Facet Joint Clinical Trial
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
10. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
11. Joint Commission Urges Patients to Speak Up About Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... is evident from the industry players that as a whole ... to the lack of promotional activities to make consumers aware ... acids. Among omega-3 ingredient sources algal oil is expected to ... vegetarian population in India . ... in growth stage of its lifecycle. Omega-3 fatty acids have ...
(Date:9/30/2014)... CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced the initiation of a ... to topotecan in subjects with extensive-stage small cell ... refractory to prior chemotherapy. Aldoxorubicin is CytRx,s modified ... has received Orphan Drug Designation for the treatment ...
(Date:9/29/2014)... SAN DIEGO , 29 septembre ... désignée Daiichi Sankyo) (TSE : 4568) et Ambit Biosciences ... d,un accord de fusion définitif en vertu duquel ... actions ordinaires en circulation d,Ambit Biosciences à 15 ... d,une offre publique d,achat qui sera suivie d,une ...
Breaking Medicine Technology:Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9
... HealthCare presented results from a global Phase II study ... detection of cerebral beta-Amyloid plaques, at the 19th World ... of the Phase II study was to investigate the ... clinical diagnosis of probable Alzheimer,s disease and Healthy Volunteers ...
... ADA,s 2009 Convention -- When Shawnae Jebbia won the ... a fairytale career. She appeared at events throughout the world, ... But Shawnae,s world unexpectedly changed when she was diagnosed with ... adventure, she had a difficult time understanding and accepting the ...
Cached Medicine Technology:Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 2Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 3Former Miss USA Shawnae Jebbia Shines with Siemens Pure 2Former Miss USA Shawnae Jebbia Shines with Siemens Pure 3
(Date:9/30/2014)... HealthDay Reporter MONDAY, ... should be the first choice of birth control for ... Pediatrics state. Although most U.S. teens opt for ... contraception -- intrauterine devices (IUDs) and contraceptive implants -- ... And they should be the "first-line" choices for teenage ...
(Date:9/30/2014)... 2014 Houstonians seeking the latest information ... visit on the Internet. Paul Vitenas, JR. M.D., ... cosmetic surgeons, has launched a new website to better ... Botox Cosmetic services. The new website can ... to the new website, Botox Cosmetic is a non-surgical ...
(Date:9/30/2014)... 2014 Thanks to generous ... Children’s Oral Health Foundation: America’s ToothFairy® (NCOHF) ... non-profit clinical partners. These organizations are part ... comprehensive educational, preventive and treatment services for ...     Just Kids Dental: $25,000 America's ...
(Date:9/30/2014)... News) -- For millions of overweight Americans, regular exercise ... threat of type 2 diabetes. However, a new ... some than for others, depending on their genes. ... not be as effective for everyone when it comes ... expert, Dr. Ruth Loos, director of the Genetics of ...
(Date:9/30/2014)... California (PRWEB) September 30, 2014 The ... to reach USD 38.75 billion by 2020 at an ... to a new study by Grand View Research, Inc. ... due to lifestyle habits such as excessive alcohol consumption ... organ failure rates is expected to serve this market ...
Breaking Medicine News(10 mins):Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 2Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 3Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 2Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 3Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 3Health News:Can Exercise Prevent Type 2 Diabetes? Your Genes May Be Key 2Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 2Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 3Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 4Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 5Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 6
... , , WASHINGTON, July 20 ... of the people who were infected with the virus were able ... others. Recent studies have begun to unravel the cause of this ... have a unique survival advantage if they have both a low ...
... , , , BEDFORD, Mass., ... leader in tubing-free insulin pump technology with its OmniPod(R) Insulin Management ... quarter 2009 on Tuesday, August 4, 2009 after the close of ... will also host a conference call at 5:00 p.m. Eastern Time ...
... , PORTLAND, Ore. July 20 Studies ... for heart disease, stroke, and delivery of premature or low birth-weight babies. ... without dental insurance - nearly twice the rate of people without medical ... care more accessible to people, Regence Life and Health ...
... growth, metastasis, researchers say , MONDAY, July 20 (HealthDay ... may contribute to aggressive breast cancer, new research shows. ... profiles" of breast cancer tumors, researchers from the Genome ... be implicated in the development of breast cancer. , ...
... , , GREENFIELD, Wis., July ... one-of-a-kind online nutritional service and meal-planning program for cancer patients. ... www.therapeasecuisine.com . Founded by cancer survivors, the program ... registered dietitians. It is available to cancer patients and health ...
... ,The team, led by Professor Matthias Mann ... of Copenhagen and the Max Planck Institute for Biochemistry in ... "This is more than just a technological achievement, ... by a factor of six, and it gives us for ...
Cached Medicine News:Health News:Genetic Variation Associated With Survival Advantage in African Americans With HIV 2Health News:Genetic Variation Associated With Survival Advantage in African Americans With HIV 3Health News:Genetic Variation Associated With Survival Advantage in African Americans With HIV 4Health News:Insulet Corporation to Report Second Quarter 2009 Financial Results on Tuesday, August 4, 2009 2Health News:More Americans Have Cell Phones Than Dental Coverage 2Health News:New Gene May Signal Aggressive Breast Cancer 2Health News:Cancer Survivors Launch New Company, TherapEase Cuisine 2
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
This is a single-action instrument that features a spring handle....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Medicine Products: